How do I buy prescription medication?

Cefaseptin Tablets for Dogs

Cefaseptin Tablets for Dogs
75mg » Priced per Tablet

  • 75mg » Priced per Tablet £0.49
  • 300mg » Priced per Tablet £0.89
  • 750mg » Priced per Tablet £1.49

Selection of 3 products from

£0.49 to £1.49

Description

Cefaseptin contains the antibiotic cefalexin. This is the antibiotic of choice for many of the skin infections which affect dogs. The main use of the antibiotic is to treat Staphylococcus intermedius infections if the skin, but this antibiotic is prescribed for many other types of infection on occasions. Cefaseptin distributes very widely around the body and achieves high concentrations in many tissues. It can be used for infections of the respiratory, urinary and reproductive systems amongst others. It is safe to give extended courses if required. Twice daily dosing is normal, at a rate of up to 25mg/kg bodyweight.

Cefaseptin 75, 300 & 750 mg tablets for dogs: 2016-04-19 15:17

Species: Dogs Therapeutic indication: Pharmaceuticals: Antimicrobials: Oral preparations: Tablets Active ingredient: Cefalexin Product:Cefaseptin 75, 300 & 750 mg tablets for dogs Product index: Cefaseptin 75, 300 & 750 mg tablets for dogs

Presentation

Beige oblong tablet. 75 mg tablets can be divided into equal halves. 300 mg and 750 mg tablets can be divided into equal halves and quarters.

Uses

For the treatment of bacterial skin infections (including deep and superficial pyoderma) caused by organisms, including Staphylococcus spp., susceptible to cefalexin. For the treatment of urinary-tract infections (including nephritis and cystitis) caused by organisms, including Escherichia coli, susceptible to cefalexin.

Dosage and administration

For oral administration. 15 mg of cefalexin per kg of bodyweight twice daily (equivalent to 30 mg per kg of bodyweight per day) for a duration of: - 14 days in case of urinary-tract infection - at least 15 days in case of superficial bacterial infection of the skin. - at least 28 days in case of deep bacterial infection of the skin. To ensure correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing. The product may be crushed or added to food if necessary. In severe or acute conditions, except in cases of known renal insufficiency (see special precautions for use in animals), the dose may be doubled.

Contra-indications, warnings, etc

Do not use in cases of known hypersensitivity to the active substance, to other cephalosporins, to other substances of the β-lactam group or to any of the excipients. Do not use in the case of resistance to cephalosporins or penicillins. Do not use in rabbits, guinea pigs, hamsters and gerbils.

Special precautions for use in animals

The need for systemic antibiotics compared with non-antibiotic alternatives for the treatment of superficial pyoderma should be carefully considered by the responsible veterinarian. As with other antibiotics which are excreted mainly by the kidneys, systemic accumulation may occur in the body when renal function is impaired. In case of known renal insufficiency, the dose should be reduced and antimicrobials known to be nephrotoxic should not be administered concurrently. This product should not be used to treat puppies of less than 1 kg of bodyweight. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local epidemiological information. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalexin and may decrease the effectiveness of treatment with other cephalosporins and penicillins, due to the potential for cross-resistance. Official, national and regional antimicrobial policies should be taken into account when the product is used.

Adverse reactions (frequency and seriousness)

In very rare cases, nausea, vomiting and/or diarrhoea have been observed in some dogs after administration. In rare cases hypersensitivity can occur. In cases of hypersensitivity reactions the treatment should be stopped. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment), - common (more than 1 but less than 10 animals in 100 animals), - uncommon (more than 1 but less than 10 animals in 1,000 animals), - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports).

Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established in bitches during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction

In order to ensure efficacy, the veterinary medicinal product should not be used in combination with bacteriostatic antibiotics. Concurrent use of first generation cephalosporins with aminoglycoside antibiotics or some diuretics such as furosemide can enhance nephrotoxicity risks.

Overdose (symptoms, emergency procedures, antidotes), if necessary

Trials performed on animals with up to 5 times the recommended twice daily dosage of 15 mg cefalexin/kg demonstrated that the product was well tolerated. Adverse reactions that may occur at the recommended dose are expected in the case of overdose. In the event of overdose, treatment should be symptomatic.

Pharmaceutical precautions

Store in the orginal packaging. Return any part used tablet to the opened blister-pack. Shelf life of the verterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: 75 mg: 16 hours, 300 mg & 750 mg: 48 hours.

Legal category

Legal category: POM-V

Packaging quantities

PVC/aluminium/OPA blister, with an aluminium foil for sealing: cardboard box of 10 blisters of 10 tablets (75 mg & 300 mg), cardboard box of 25 blisters of 10 tablets (75 mg & 300 mg), cardboard box of 12 blisters of 6 tablets (750 mg) and cardboard box of 25 blisters of 6 tablets (750 mg). Not all pack sizes may be marketed.

Further information

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing Authorisation Number

Cefaseptin 75 mg tablets for dogs Vm 08007/4141 Cefaseptin 300 mg tablets for dogs Vm 08007/4142 Cefaseptin 750 mg tablets for dogs Vm 08007/4143

Significant changes

GTIN

GTIN description:Cefaseptin 75 mg 100 tablets GTIN:03605874393899 GTIN description:Cefaseptin 75 mg 250 tablets GTIN:03605874393974 GTIN description:Cefaseptin 300 mg 100tablets GTIN:03605874393943 GTIN description:Cefaseptin 300 mg 250 tablets GTIN:03605874393998 GTIN description:Cefaseptin 750 mg 72 tablets GTIN:03605874394056 GTIN description:Cefaseptin 750 mg 150 tablets GTIN:03605874394018

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

300mg » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cefaseptin 300 mg tablets for dogs

  1. QUALITATIVE AND QUANTITATIVE COMPOSITION

One tablet contains:

Active substance: cefalexin (as cefalexin monohydrate) 300 mg

For the full list of excipients, see section 6.1.

  1. PHARMACEUTICAL FORM

Beige oblong tablet. The tablet can be divided into equal halves and quarters.

  1. CLINICAL PARTICULARS

4.1 Target species

Dogs

4.2 Indications for use, specifying the target species

For the treatment of bacterial skin infections (including deep and superficial pyoderma) caused by organisms, including Staphylococcus spp., susceptible to cefalexin.

For the treatment of urinary-tract infections (including nephritis and cystitis) caused by organisms, including Escherichia coli, susceptible to cefalexin.

4.3 Contraindications

Do not use in cases of known hypersensitivity to the active substance, to other cephalosporins, to other substances of the β-lactam group or to any of the excipients. Do not use in the case of resistance to cephalosporins or penicillins.

Do not use in rabbits, guinea pigs, hamsters and gerbils.

4.4 Special warnings for each target species

None

4.5 Special precautions for use

Special precautions for use in animals

The need for systemic antibiotics compared with non-antibiotic alternatives for the treatment of superficial pyoderma should be carefully considered by the responsible veterinarian.

As with other antibiotics which are excreted mainly by the kidneys, systemic accumulation may occur in the body when renal function is impaired. In case of known renal insufficiency, the dose should be reduced and antimicrobials known to be nephrotoxic should not be administered concurrently. This product should not be used to treat puppies of less than 1 kg of bodyweight.

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local epidemiological information.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalexin and may decrease the effectiveness of treatment with other cephalosporins and penicillins, due to the potential for cross-resistance.

Official, national and regional antimicrobial policies should be taken into account when the product is used.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious. Do not handle this product if you know you are sensitised or if you have been advised not to work with such preparations. Handle this product with great care to avoid exposure, taking all recommended precautions. Wash hands after use. If you develop symptoms following exposure such as skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more-serious symptoms and require urgent medical attention.

4.6 Adverse reactions (frequency and seriousness)

In very rare cases, nausea, vomiting and/or diarrhoea have been observed in some dogs after administration. In rare cases hypersensitivity can occur.

In cases of hypersensitivity reactions the treatment should be stopped.

The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals ) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports).

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established in bitches during pregnancy and lactation. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

In order to ensure efficacy, the veterinary medicinal product should not be used in combination with bacteriostatic antibiotics. Concurrent use of first generation cephalosporins with aminoglycoside antibiotics or some diuretics such as furosemide can enhance nephrotoxicity risks.

4.9 Amounts to be administered and administration route

For oral administration. 15 mg of cefalexin per kg of bodyweight twice daily (equivalent to 30 mg per kg of bodyweight per day) for a duration of: - 14 days in case of urinary-tract infection - at least 15 days in case of superficial bacterial infection of the skin. - at least 28 days in case of deep bacterial infection of the skin.

To ensure correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing. The product may be crushed or added to food if necessary. In severe or acute conditions, except in cases of known renal insufficiency (see section 4.5), the dose may be doubled.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Trials performed on animals with up to 5 times the recommended twice daily dosage of 15 mg cefalexin/kg demonstrated that the product was well tolerated.

Adverse reactions that may occur at the recommended dose are expected in the case of overdose. In the event of overdose, treatment should be symptomatic.

4.11 Withdrawal period(s)

Not applicable

  1. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antibacterials for systemic use, first generation cephalosporins ATCvet code: QJ01DB01 5.1 Pharmacodynamic properties

Cefalexin acts by inhibiting the nucleopeptide synthesis of the bacterial wall. Cephalosporins interfere with the enzymes of transpeptidation making it unable to cross-link the peptidoglycans of the bacterial cell wall. The glycan cross-linking is essential for the cell to build its cell wall. Inhibition of the biosynthesis results to a weakened cell wall, which eventually ruptures to osmotic pressure. The combined action results in cell lysis and filament formation.

Cefalexin is active against a wide range of Gram-positive (e.g. Staphylococcus spp.) and Gram-negative (e.g. Escherichia coli) aerobic bacteria. The following breakpoints are recommended by the CLSI in dogs for E.coli and Staphylococcus spp:

MIC (µg/mL) Interpretation ≤2 Sensitive 4 Intermediate ≥8 Resistant

Resistance to cefalexin can be due to one of the following mechanisms of resistance. Firstly, the production of cephalosporinases, that inactivate the antibiotic by hydrolysis of the β-lactam ring, is the most prevalent mechanism among Gram-negative bacteria. This resistance is transmitted by plasmid or chromosomally. Secondly, a decreased affinity of the PBPs (penicillin-binding proteins) for beta-lactam drugs is frequently involved for beta-lactam resistant Gram-positive bacteria. Lastly, efflux pumps, extruding the antibiotic from the bacterial cell, and structural changes in porins, reducing passive diffusion of the drug through the cell wall, may contribute to improve the resistant phenotype of a bacterium. Well-known cross-resistance (involving the same resistance mechanism) exists between antibiotics belonging to the beta-lactam group due to structural similarities. It occurs with beta-lactamases enzymes, structural changes in porins or variations in efflux pumps. Co-resistance (different resistance mechanisms involved) has been described in E.coli due to a plasmid harbouring various resistance genes.

5.2 Pharmacokinetic particulars

After single oral administration of the recommended dosage of 15 mg of cefalexin per kg of bodyweight to Beagle dogs, plasma concentrations were observed within 30 minutes. The plasma peak was observed at 1.3 hour with a plasma concentration of 18.2 mg/ml. The bioavailability of the active was over 90 %. Cefalexin was detected until 24 hours after the administration. The first urine specimen was collected within 2 to 12 hours with peak concentrations of cefalexin measured at 430 to 2758 mg/ml within 12 hours.

After repeated oral administration of the same dosage, twice a day for 7 days, plasma peaks occurred 2 hours later with a concentration of 20 mg/ml. Over the treatment period, concentrations were maintained above 1 mg/ml. The mean elimination half-life is 2 hours. Skin levels were around 5.8 to 6.6 mg/g, 2 hours after treatment.

  1. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose monohydrate Povidone K30 Croscarmellose sodium Microcrystalline cellulose Porcine liver powder Yeast Crospovidone Sodium stearyl fumarate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: 48 hours.

6.4. Special precautions for storage

Store in the original package. Return any part used tablet to the opened blister-pack.

6.5 Nature and composition of immediate packaging

PVC/aluminium/OPA – PVC blister Cardboard box of 1 blister of 10 tablets Cardboard box of 10 blisters of 10 tablets Cardboard box of 25 blisters of 10 tablets Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

  1. MARKETING AUTHORISATION HOLDER

Vetoquinol UK Limited Steadings Barn Pury Hill Business Park
Nr Alderton Towcester Northamptonshire NN12 7LS

  1. MARKETING AUTHORISATION NUMBER

Vm 08007/4142

  1. DATE OF FIRST AUTHORISATION

12 January 2016

  1. DATE OF REVISION OF THE TEXT

September 2018

Approved 07 September 2018

750mg » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cefaseptin 750 mg tablets for dogs

  1. QUALITATIVE AND QUANTITATIVE COMPOSITION

One tablet contains:

Active substance: cefalexin (as cefalexin monohydrate) 750 mg

For the full list of excipients, see section 6.1.

  1. PHARMACEUTICAL FORM

Beige oblong tablet. The tablet can be divided into equal halves and quarters.

  1. CLINICAL PARTICULARS

4.1 Target species

Dogs

4.2 Indications for use, specifying the target species

For the treatment of bacterial skin infections (including deep and superficial pyoderma) caused by organisms, including Staphylococcus spp., susceptible to cefalexin.

For the treatment of urinary-tract infections (including nephritis and cystitis) caused by organisms, including Escherichia coli, susceptible to cefalexin.

4.3 Contraindications

Do not use in cases of known hypersensitivity to the active substance, to other cephalosporins, to other substances of the β-lactam group or to any of the excipients. Do not use in the case of resistance to cephalosporins or penicillins.

Do not use in rabbits, guinea pigs, hamsters and gerbils.

4.4 Special warnings for each target species

None 4.5 Special precautions for use

Special precautions for use in animals

The need for systemic antibiotics compared with non-antibiotic alternatives for the treatment of superficial pyoderma should be carefully considered by the responsible veterinarian.

As with other antibiotics which are excreted mainly by the kidneys, systemic accumulation may occur in the body when renal function is impaired. In case of known renal insufficiency, the dose should be reduced and antimicrobials known to be nephrotoxic should not be administered concurrently. This product should not be used to treat puppies of less than 1 kg of bodyweight.

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local epidemiological information.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalexin and may decrease the effectiveness of treatment with other cephalosporins and penicillins, due to the potential for cross-resistance.

Official, national and regional antimicrobial policies should be taken into account when the product is used.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious. Do not handle this product if you know you are sensitised or if you have been advised not to work with such preparations. Handle this product with great care to avoid exposure, taking all recommended precautions. Wash hands after use. If you develop symptoms following exposure such as skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more-serious symptoms and require urgent medical attention.

4.6 Adverse reactions (frequency and seriousness)

In very rare cases, nausea, vomiting and/or diarrhoea have been observed in some dogs after administration. In rare cases hypersensitivity can occur.

In cases of hypersensitivity reactions the treatment should be stopped. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals ) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports).

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established in bitches during pregnancy and lactation. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

In order to ensure efficacy, the veterinary medicinal product should not be used in combination with bacteriostatic antibiotics. Concurrent use of first generation cephalosporins with aminoglycoside antibiotics or some diuretics such as furosemide can enhance nephrotoxicity risks.

4.9 Amounts to be administered and administration route

For oral administration. 15 mg of cefalexin per kg of bodyweight twice daily (equivalent to 30 mg per kg of bodyweight per day) for a duration of: - 14 days in case of urinary-tract infection - at least 15 days in case of superficial bacterial infection of the skin. - at least 28 days in case of deep bacterial infection of the skin.

To ensure correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing. The product may be crushed or added to food if necessary. In severe or acute conditions, except in cases of known renal insufficiency (see section 4.5), the dose may be doubled.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Trials performed on animals with up to 5 times the recommended twice daily dosage of 15 mg cefalexin/kg demonstrated that the product was well tolerated.

Adverse reactions that may occur at the recommended dose are expected in the case of overdose. In the event of overdose, treatment should be symptomatic.

4.11 Withdrawal period(s)

Not applicable.

  1. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antibacterials for systemic use, first generation cephalosporins ATCvet code: QJ01DB01

5.1 Pharmacodynamic properties

Cefalexin acts by inhibiting the nucleopeptide synthesis of the bacterial wall. Cephalosporins interfere with the enzymes of transpeptidation making it unable to cross-link the peptidoglycans of the bacterial cell wall. The glycan cross-linking is essential for the cell to build its cell wall. Inhibition of the biosynthesis results to a weakened cell wall, which eventually ruptures to osmotic pressure. The combined action results in cell lysis and filament formation.

Cefalexin is active against a wide range of Gram-positive (e.g. Staphylococcus spp.) and Gram-negative (e.g. Escherichia coli) aerobic bacteria. The following breakpoints are recommended by the CLSI in dogs for E.coli and Staphylococcus spp:

MIC (µg/mL) Interpretation ≤2 Sensitive 4 Intermediate ≥8 Resistant

Resistance to cefalexin can be due to one of the following mechanisms of resistance. Firstly, the production of cephalosporinases, that inactivate the antibiotic by hydrolysis of the β-lactam ring, is the most prevalent mechanism among Gram-negative bacteria. This resistance is transmitted by plasmid or chromosomally. Secondly, a decreased affinity of the PBPs (penicillin-binding proteins) for beta-lactam drugs is frequently involved for beta-lactam resistant Gram-positive bacteria. Lastly, efflux pumps, extruding the antibiotic from the bacterial cell, and structural changes in porins, reducing passive diffusion of the drug through the cell wall, may contribute to improve the resistant phenotype of a bacterium. Well-known cross-resistance (involving the same resistance mechanism) exists between antibiotics belonging to the beta-lactam group due to structural similarities. It occurs with beta-lactamases enzymes, structural changes in porins or variations in efflux pumps. Co-resistance (different resistance mechanisms involved) has been described in E.coli due to a plasmid harbouring various resistance genes.

5.2 Pharmacokinetic particulars

After single oral administration of the recommended dosage of 15 mg of cefalexin per kg of bodyweight to Beagle dogs, plasma concentrations were observed within 30 minutes. The plasma peak was observed at 1.3 hour with a plasma concentration of 18.2 mg/ml. The bioavailability of the active was over 90 %. Cefalexin was detected until 24 hours after the administration. The first urine specimen was collected within 2 to 12 hours with peak concentrations of cefalexin measured at 430 to 2758 mg/ml within 12 hours.

After repeated oral administration of the same dosage, twice a day for 7 days, plasma peaks occurred 2 hours later with a concentration of 20 mg/ml. Over the treatment period, concentrations were maintained above 1 mg/ml. The mean elimination half-life is 2 hours. Skin levels were around 5.8 to 6.6 mg/g, 2 hours after treatment.

  1. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose monohydrate Povidone K30 Croscarmellose sodium Microcrystalline cellulose Porcine liver powder Yeast Crospovidone Sodium stearyl fumarate

6.2 Incompatibilities

Not applicable

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: 48 hours.

6.4. Special precautions for storage

Store in the original package. Return any part used tablet to the opened blister-pack.

6.5 Nature and composition of immediate packaging

PVC/aluminium/OPA – PVC blister Cardboard box of 1 blister of 6 tablets Cardboard box of 2 blisters of 6 tablets Cardboard box of 12 blisters of 6 tablets Cardboard box of 25 blisters of 6 tablets

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER

Vetoquinol UK Limited Steadings Barn Pury Hill Business Park
Nr Alderton Towcester Northamptonshire NN12 7LS

  1. MARKETING AUTHORISATION NUMBER

Vm 08007/4143

  1. DATE OF FIRST AUTHORISATION

12 January 2016

  1. DATE OF REVISION OF THE TEXT

September 2018

Approved 07 September 2018

75mg » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cefaseptin 75mg tablets for dogs

  1. QUALITATIVE AND QUANTITATIVE COMPOSITION

One tablet contains:

Active substance: cefalexin (as cefalexin monohydrate) 75 mg

For the full list of excipients, see section 6.1.

  1. PHARMACEUTICAL FORM

Beige oblong tablet. The tablet can be divided into equal halves.

  1. CLINICAL PARTICULARS

4.1 Target species

Dogs

4.2 Indications for use, specifying the target species

For the treatment of bacterial skin infections (including deep and superficial pyoderma) caused by organisms, including Staphylococcus spp., susceptible to cefalexin.

For the treatment of urinary-tract infections (including nephritis and cystitis) caused by organisms, including Escherichia coli, susceptible to cefalexin.

4.3 Contraindications

Do not use in cases of known hypersensitivity to the active substance, to other cephalosporins, to other substances of the β-lactam group or to any of the excipients. Do not use in the case of resistance to cephalosporins or penicillins.

Do not use in rabbits, guinea pigs, hamsters and gerbils.

4.4 Special warnings for each target species

None 4.5 Special precautions for use

Special precautions for use in animals The need for systemic antibiotics compared with non-antibiotic alternatives for the treatment of superficial pyoderma should be carefully considered by the responsible veterinarian.

As with other antibiotics which are excreted mainly by the kidneys, systemic accumulation may occur in the body when renal function is impaired. In case of known renal insufficiency, the dose should be reduced and antimicrobials known to be nephrotoxic should not be administered concurrently. This product should not be used to treat puppies of less than 1 kg of bodyweight.

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local epidemiological information.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalexin and may decrease the effectiveness of treatment with other cephalosporins and penicillins, due to the potential for cross-resistance.

Official, national and regional antimicrobial policies should be taken into account when the product is used.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious. Do not handle this product if you know you are sensitised or if you have been advised not to work with such preparations. Handle this product with great care to avoid exposure, taking all recommended precautions. Wash hands after use. If you develop symptoms following exposure such as skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more-serious symptoms and require urgent medical attention.

4.6 Adverse reactions (frequency and seriousness)

In very rare cases, nausea, vomiting and/or diarrhoea have been observed in some dogs after administration. In rare cases hypersensitivity can occur.

In cases of hypersensitivity reactions the treatment should be stopped.

The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals ) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports).

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established in bitches during pregnancy and lactation. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

In order to ensure efficacy, the veterinary medicinal product should not be used in combination with bacteriostatic antibiotics. Concurrent use of first generation cephalosporins with aminoglycoside antibiotics or some diuretics such as furosemide can enhance nephrotoxicity risks.

4.9 Amounts to be administered and administration route

For oral administration. 15 mg of cefalexin per kg of bodyweight twice daily (equivalent to 30 mg per kg of bodyweight per day) for a duration of: - 14 days in case of urinary-tract infection - at least 15 days in case of superficial bacterial infection of the skin. - at least 28 days in case of deep bacterial infection of the skin.

To ensure correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing. The product may be crushed or added to food if necessary. In severe or acute conditions, except in cases of known renal insufficiency (see section 4.5), the dose may be doubled.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Trials performed on animals with up to 5 times the recommended twice daily dosage of 15 mg cefalexin/kg demonstrated that the product was well tolerated.

Adverse reactions that may occur at the recommended dose are expected in the case of overdose. In the event of overdose, treatment should be symptomatic.

4.11 Withdrawal period(s)

Not applicable

  1. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antibacterials for systemic use, first generation cephalosporins ATCvet code: QJ01DB01

5.1 Pharmacodynamic properties

Cefalexin acts by inhibiting the nucleopeptide synthesis of the bacterial wall. Cephalosporins interfere with the enzymes of transpeptidation making it unable to cross-link the peptidoglycans of the bacterial cell wall. The glycan cross-linking is essential for the cell to build its cell wall. Inhibition of the biosynthesis results to a weakened cell wall, which eventually ruptures to osmotic pressure. The combined action results in cell lysis and filament formation.

Cefalexin is active against a wide range of Gram-positive (e.g. Staphylococcus spp.) and Gram-negative (e.g. Escherichia coli) aerobic bacteria.

The following breakpoints are recommended by the CLSI in dogs for E.coli and Staphylococcus spp:

MIC (µg/mL) Interpretation ≤2 Sensitive 4 Intermediate ≥8 Resistant

Resistance to cefalexin can be due to one of the following mechanisms of resistance. Firstly, the production of cephalosporinases, that inactivate the antibiotic by hydrolysis of the β-lactam ring, is the most prevalent mechanism among Gram-negative bacteria. This resistance is transmitted by plasmid or chromosomally. Secondly, a decreased affinity of the PBPs (penicillin-binding proteins) for beta-lactam drugs is frequently involved for beta-lactam resistant Gram-positive bacteria. Lastly, efflux pumps, extruding the antibiotic from the bacterial cell, and structural changes in porins, reducing passive diffusion of the drug through the cell wall, may contribute to improve the resistant phenotype of a bacterium. Well-known cross-resistance (involving the same resistance mechanism) exists between antibiotics belonging to the beta-lactam group due to structural similarities. It occurs with beta-lactamases enzymes, structural changes in porins or variations in efflux pumps. Co-resistance (different resistance mechanisms involved) has been described in E.coli due to a plasmid harbouring various resistance genes.

5.2 Pharmacokinetic particulars

After single oral administration of the recommended dosage of 15 mg of cefalexin per kg of bodyweight to Beagle dogs, plasma concentrations were observed within 30 minutes. The plasma peak was observed at 1.3 hour with a plasma concentration of 18.2 mg/ml. The bioavailability of the active was over 90 %. Cefalexin was detected until 24 hours after the administration. The first urine specimen was collected within 2 to 12 hours with peak concentrations of cefalexin measured at 430 to 2758 mg/ml within 12 hours.

After repeated oral administration of the same dosage, twice a day for 7 days, plasma peaks occurred 2 hours later with a concentration of 20 mg/ml. Over the treatment period, concentrations were maintained above 1 mg/ml. The mean elimination half-life is 2 hours. Skin levels were around 5.8 to 6.6 mg/g, 2 hours after treatment.

  1. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose monohydrate Povidone K30 Croscarmellose sodium Microcrystalline cellulose Porcine liver powder Yeast Crospovidone Sodium stearyl fumarate

6.2 Incompatibilities

Not applicable

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years Shelf life after first opening the immediate packaging: 16 hours.

6.4. Special precautions for storage

Store in the original package. Return any part used tablet to the opened blister-pack.

6.5 Nature and composition of immediate packaging

PVC/aluminium/OPA – PVC blister Cardboard box of 1 blister of 10 tablets Cardboard box of 10 blisters of 10 tablets Cardboard box of 25 blisters of 10 tablets Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER

Vetoquinol UK Limited Steadings Barn Pury Hill Business Park
Nr Alderton Towcester Northamptonshire NN12 7LS

  1. MARKETING AUTHORISATION NUMBER

Vm 08007/4141

  1. DATE OF FIRST AUTHORISATION

12 January 2016

  1. DATE OF REVISION OF THE TEXT

September 2018

Approved 07 September 2018

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews

Q & A

There are currently no questions for Cefaseptin Tablets for Dogs - be the first to ask one!